To hear about similar clinical trials, please enter your email below
Trial Title:
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Young Adults With Acute Lymphoblastic Leukemia
NCT ID:
NCT06446661
Condition:
Acute Lymphoblastic Leukemia
Conditions: Official terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Conditions: Keywords:
Oral Chemotherapy
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
High Intensity
Description:
Daily texts
Arm group label:
High Intensity
Intervention type:
Other
Intervention name:
No Text Messagings
Description:
Standard Care
Arm group label:
Low Intensity
Intervention type:
Other
Intervention name:
Low Intensity Text Messaging
Description:
Weekly Texts
Arm group label:
Low Intensity
Summary:
The purpose of this section is to learn how text message reminders might help with
regularly taking chemotherapy medications for Adolescents and Young Adults (AYA) with
Acute Lymphoblastic leukemia (ALL).
Detailed description:
This study aims to compare adherence to oral mercaptopurine and methotrexate during the
first 84-day cycle of maintenance therapy for adolescent and young adult patients with
Acute Lymphoblastic Leukemia on pediatric-based regimens between those who receive the
high intensity text message intervention and those who receive standard-of-care. It is
believed that high-intensity text messages will increase patient adherence within cycle
1.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Age of 15-39 years-old at the time of initial ALL diagnosis
- Diagnosed with ALL
- Currently receiving treatment with pediatric-based regimen that includes maintenance
with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins
with the start of maintenance, so enrollment occurs prior to the start of
maintenance.
Exclusion Criteria:
- Patient or caregiver who would receive text message reminders does not have a cell
phone that receives text messages
- Patient does not wish to participate
Gender:
All
Minimum age:
15 Years
Maximum age:
39 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
University of Chicago Medicine Comprehensive Cancer Center
Address:
City:
Chicago
Zip:
60637
Country:
United States
Contact:
Last name:
Clinical Trials Intake
Phone:
855-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Wendy Stock
Email:
Principal Investigator
Start date:
December 15, 2024
Completion date:
June 15, 2028
Lead sponsor:
Agency:
University of Chicago
Agency class:
Other
Source:
University of Chicago
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06446661
